130 related articles for article (PubMed ID: 38287534)
1. Possible effects of plasminogen activator inhibitor-1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides.
Fujimura T; Ohuchi K; Ikawa T; Kambayashi Y; Amagai R; Furudate S; Asano Y
Hematol Oncol; 2024 Jan; 42(1):e3244. PubMed ID: 38287534
[TBL] [Abstract][Full Text] [Related]
2. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9.
Vacca A; Moretti S; Ribatti D; Pellegrino A; Pimpinelli N; Bianchi B; Bonifazi E; Ria R; Serio G; Dammacco F
Eur J Cancer; 1997 Sep; 33(10):1685-92. PubMed ID: 9389934
[TBL] [Abstract][Full Text] [Related]
3. Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene.
Tamer F; Gulekon A
J Coll Physicians Surg Pak; 2021 Jun; 31(6):716-718. PubMed ID: 34102787
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides.
Rasheed H; Tolba Fawzi MM; Abdel-Halim MR; Eissa AM; Mohammed Salem N; Mahfouz S
Am J Dermatopathol; 2010 Apr; 32(2):162-9. PubMed ID: 20051814
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
6. Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression.
Vacca A; Ribatti D; Ria R; Pellegrino A; Bruno M; Merchionne F; Dammacco F
Dev Immunol; 2000; 7(2-4):77-88. PubMed ID: 11097203
[TBL] [Abstract][Full Text] [Related]
7. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
[TBL] [Abstract][Full Text] [Related]
8. Interventions for mycosis fungoides.
Valipour A; Jäger M; Wu P; Schmitt J; Bunch C; Weberschock T
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD008946. PubMed ID: 32632956
[TBL] [Abstract][Full Text] [Related]
9. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides.
Furudate S; Fujimura T; Kakizaki A; Kambayashi Y; Asano M; Watabe A; Aiba S
Exp Dermatol; 2016 Feb; 25(2):107-12. PubMed ID: 26441016
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
11. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.
Kakinuma T; Sugaya M; Nakamura K; Kaneko F; Wakugawa M; Matsushima K; Tamaki K
J Am Acad Dermatol; 2003 Jan; 48(1):23-30. PubMed ID: 12522366
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Grzegrzolka J; Piotrowska A; Gomulkiewicz A; Glatzel-Plucinska N; Olbromski M; Podhorska-Okolow M; Szepietowski JC; Dziegiel P
Anticancer Res; 2016 Sep; 36(9):4575-82. PubMed ID: 27630298
[TBL] [Abstract][Full Text] [Related]
13. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
14. Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
Allen PB; McCook-Veal AA; Switchenko JM; Paulino DM; Niyogusaba T; Baird KM; Tarabadkar ES; Lechowicz MJ
Cancer; 2023 Feb; 129(4):541-550. PubMed ID: 36523150
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
16. Dermal fibroblasts promote cancer cell proliferation and exhibit fibronectin overexpression in early mycosis fungoides.
Beksaç B; Gleason L; Baik S; Ringe JM; Porcu P; Nikbakht N
J Dermatol Sci; 2022 Apr; 106(1):53-60. PubMed ID: 35331619
[TBL] [Abstract][Full Text] [Related]
17. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
18. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
[TBL] [Abstract][Full Text] [Related]
19. Mycosis Fungoides and Variants of Mycosis Fungoides: A Retrospective Study of 93 Patients in a Chinese Population at a Single Center.
Luo Y; Liu Z; Liu J; Liu Y; Zhang W; Zhang Y
Ann Dermatol; 2020 Feb; 32(1):14-20. PubMed ID: 33911704
[TBL] [Abstract][Full Text] [Related]
20. A CD30(-) Transformed Mycosis Fungoides Case Responding Very Well to Systemic Bexarotene and Methotrexate.
Zindanci I; Kavala M; Turkoğlu Z; Can B; Ozturk E; Zemheri E; Akbulak O; Mansuroglu C; Topaloğlu Demir F
Int J Low Extrem Wounds; 2014 Jun; 13(2):127-129. PubMed ID: 24872469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
